

ASX RELEASE

ATO confirms availability of CGT rollover relief in draft Class Ruling

Melbourne, Australia, 14 July 2020: [Sienna Cancer Diagnostics \(ASX: SDX\)](#) (“Sienna” or “the Company”) is pleased to announce the receipt of a draft Class Ruling from the Australian Taxation Office (ATO) confirming availability of capital gains tax rollover relief to resident Australian Sienna shareholders holding shares on capital account.

The Class Ruling means Australian resident shareholders holding Sienna’s shares on capital account can elect to have any capital gains on exchange of Sienna ordinary shares for BARD1 Life Sciences Ltd (BARD1) ordinary shares assessed when they deal in shares of BARD1.

A final Class Ruling will be provided once:

- Sienna’s shareholders approve the merger of the entities at the meeting of members scheduled for 15 July;
- the Federal Court provides approval of the Scheme of Arrangement at a hearing scheduled for 17 July; and
- the companies merge (expected to occur 28 July 2020).

ENDS

For Further Information, please contact:

Tony Di Pietro, Executive Director, CFO & Company Secretary
Sienna Cancer Diagnostics Ltd
tdipietro@siennadiagnostics.com.au
+61 3 9548 7586

The release of this announcement was authorised by Tony Di Pietro, Company Secretary.

About Sienna Cancer Diagnostics Ltd.

Sienna is a medical technology company that develops and commercialises diagnostic tests to assist in the early and accurate diagnosis of cancer, enabling improved treatment and patient outcomes. Sienna’s first product, hTERT, a test that aids in the diagnosis of bladder cancer, has been launched and is being commercialised through a growing network of distribution partners globally.

Sienna entered the global liquid biopsy market in 2019 via the strategic acquisition of a “Molecular Net” technology called SIEN-NET™. The first commercial embodiment of SIEN-NET is EXO-NET™, which has been specifically designed to purify a patient sample for cancer-associated exosomes.

The Company recently announced the signing of an exclusive worldwide licence agreement with the University of Adelaide to develop and commercialise a unique cancer probe, SubB2M, which binds to a unique sugar molecule only present in human cancers and can detect its presence in the serum of cancer patients. SubB2M has the potential to detect cancer in a range of testing modalities such as liquid biopsies, immunoassays, circulating tumor cell assays and PET imaging.

